Percutaneous transluminal revascularization for iliac occlusive disease: long-term outcomes in TransAtlantic Inter-Society Consensus A and B lesions
- PMID: 15818461
- DOI: 10.1007/s10016-005-0010-8
Percutaneous transluminal revascularization for iliac occlusive disease: long-term outcomes in TransAtlantic Inter-Society Consensus A and B lesions
Abstract
Percutaneous transluminal intervention for atherosclerotic iliac occlusive disease is now commonplace. We examine the long-term outcomes of TransAtlantic Inter-Society Consensus (TASC) A and B lesions. We performed a retrospective anonymous analysis of records from patients who underwent iliac artery angioplasty with or without stenting between January 1990 and June 1999. Indications for intervention were symptomatic claudication (77%) or critical ischemia (23%). Altogether, 276 patients (all men; average age 64 +/- 11 years range 32-87 years) underwent 394 interventions. Co-morbidities included hypertension (61%), hypercholesterolemia (45%), diabetes (28%), and chronic renal insufficiency (26%). A total of the 62% of the lesions were TASC category A, and the remainder were category B. Of the 394 primary interventions, 51% included placement of stents. Technical success (defined by < 30% residual stenosis) was achieved in 98% of treated vessels. The procedure-related mortality rate was 1.8% at 30 days and 4.7% at 90 days; the procedure-related complication rate was 7%. Hemodynamic success (defined as a rise in the ankle/branchial index > 0.15) was achieved in 82%. The average Society for Vascular Surgery symptom score was 3.4 +/- 0.9 before intervention, which improved to 1.9 +/- 0.8 following intervention. Within 3 months, 84% of patients demonstrated clinical improvement. Patient survival by life-table analysis was 38% at 10 years. The cumulative assisted patency rate was 71 +/- 7% at 10 years. The presence of two-vessel femoral runoff, two or more patent tibial vessels, or both was associated with improved patency. Limb salvage was 95 +/- 2% and 87 +/- 9% at 5 and 10 years, respectively. Using Cox proportional hazards analysis, the presence of hypertension, hypercholesterolemia, or chronic renal insufficiency was associated with the occurrence of primary failure, whereas increased patency intervals were associated with the presence of immediate hemodynamic improvement. Use of a stent did not influence outcome. Endoluminal iliac intervention for TASC A and B lesions is a safe, durable intervention in patients with good femoral and tibial runoff. The presence of hypertension, hypercholesterolemia, or poor tibial runoff is associated with failure.
Similar articles
-
Long-term outcomes and predictors of iliac angioplasty with selective stenting.J Vasc Surg. 2005 Sep;42(3):466-75. doi: 10.1016/j.jvs.2005.05.002. J Vasc Surg. 2005. PMID: 16171589
-
Iliac artery stenting versus surgical reconstruction for TASC (TransAtlantic Inter-Society Consensus) type B and type C iliac lesions.J Vasc Surg. 2003 Aug;38(2):272-8. doi: 10.1016/s0741-5214(03)00411-7. J Vasc Surg. 2003. PMID: 12891108
-
Subintimal angioplasty of chronic total occlusion in iliac arteries: a safe and durable option.J Vasc Surg. 2011 Feb;53(2):367-73. doi: 10.1016/j.jvs.2010.08.073. Epub 2010 Oct 27. J Vasc Surg. 2011. PMID: 21030201
-
Iliac artery angioplasty : technique and results.Acta Chir Belg. 2004 Oct;104(5):532-9. doi: 10.1080/00015458.2004.11679610. Acta Chir Belg. 2004. PMID: 15571019 Review.
-
Percutaneous transluminal angioplasty and stenting for iliac artery occlusive disease.Surg Clin North Am. 1999 Jun;79(3):575-96. doi: 10.1016/s0039-6109(05)70025-6. Surg Clin North Am. 1999. PMID: 10410688 Review.
Cited by
-
DISCOVER: Dutch Iliac Stent trial: COVERed balloon-expandable versus uncovered balloon-expandable stents in the common iliac artery: study protocol for a randomized controlled trial.Trials. 2012 Nov 19;13:215. doi: 10.1186/1745-6215-13-215. Trials. 2012. PMID: 23164097 Free PMC article. Clinical Trial.
-
Factors associated with outcome of endovascular treatment of iliac occlusive disease: a single-center experience.J Vasc Bras. 2018 Jan-Mar;17(1):3-9. doi: 10.1590/1677-5449.003817. J Vasc Bras. 2018. PMID: 29930675 Free PMC article.
-
Advanced age and disease predict lack of symptomatic improvement after endovascular iliac treatment in male veterans.Yale J Biol Med. 2015 Mar 4;88(1):85-91. eCollection 2015 Mar. Yale J Biol Med. 2015. PMID: 25745377 Free PMC article.
-
Long-term Results of Reconstructive Surgery for the Unilateral Aortoiliac Occlusive Disease and Future Risks of Contralateral Iliac Events.Ann Vasc Dis. 2010;3(1):60-7. doi: 10.3400/avd.AVDoa09033. Epub 2010 Jul 21. Ann Vasc Dis. 2010. PMID: 23555389 Free PMC article.
-
The impact of inflow treatment for claudicants with both aortoiliac and femoropopliteal occlusive disease.Surg Today. 2017 Mar;47(3):293-300. doi: 10.1007/s00595-016-1399-0. Epub 2016 Sep 1. Surg Today. 2017. PMID: 27586013
MeSH terms
LinkOut - more resources
Full Text Sources